Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ABTS vs ATHA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATHA Captures Overall Composite Edge (56.2 HOLD vs 50.5 HOLD), While ABTS Leads 3–2 on Growth & Valuation Pillars

ATHA Overall Winner 6-Pillar Tally: ABTS 3 – 2 ATHA (1 Tie) Matrix Metrics: ABTS 2 – 6 ATHA

As of Nov 16, 2026, Athira Pharma, Inc. (ATHA) captures the overall head-to-head institutional edge over Abits Group Inc (ABTS) on higher Unified Composite conviction (56.2/100 HOLD vs. 50.5/100 HOLD) after splitting the core matrix 6–2 (led by Growth & Scale, Profitability & Quality), while ABTS wins 3–2 across the 6-pillar growth and valuation breakdown. ABTS trades at $0.31 (N/M Forward P/E, -46.3% operating margin) versus ATHA at $6.75 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ATHA earns the overall head-to-head edge with a stronger Unified Composite Score (56.2/100 HOLD vs. ABTS 50.5/100 HOLD) and 6.17β · 241% Vol risk profile, whereas ABTS leads top-line expansion (-20.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ABTS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.8); meanwhile ATHA trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 56.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABTS vs ATHA
ABTS NASDAQ
Abits Group Inc Ordinary Shares
Finance Services
$0.31
-6.33% 1D
Market Cap $1.1M
TTM Revenue $8.3M
Forward P/E N/M
Beta / 30D Vol 1.70β · 224% Vol
Unified Composite Score
50.5 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.8%), weak momentum, RSI 17
RSI-14: 16.8 · SMA20: $0.77 · SMA50: $1.07
ATHA NASDAQ Head-to-Head Winner
Athira Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.75
-6.12% 1D
Market Cap $26.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 6.17β · 241% Vol
Unified Composite Score
56.2 / 100 HOLD
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (23.0% over 20 days), RSI 57
RSI-14: 56.6 · SMA20: $6.36 · SMA50: $5.14

6-Pillar Scorecard Institutional Category Breakdown (ABTS 3 – 2 ATHA)

Columns: Metric · ABTS · ATHA
1. Valuation Multiples ABTS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.4x N/M
2. Growth & Scale ATHA
Revenue Growth (YoY) -20.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $8.3M N/A
Market Cap $1.1M $26.6M
3. Profitability & Quality ATHA
Gross Margin 23.7% N/A
Operating Margin -46.3% 0.0%
Net Profit Margin -60.8% 0.0%
Return on Equity (ROE) -60.0% -89.4%
4. Balance Sheet & Cash Flow ABTS
Cash Generation (TTM) $73,322 EBITDA N/A
Cash Flow Margin 0.9% EBITDA Mgn N/A
Net Cash / Leverage $1.8M Net Debt (0.24x D/E) $6.79 Book/Sh · -89.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat ABTS
OpEx & R&D Intensity 70.0% of Rev ($5.8M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Capital Markets Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABTS (2) vs ATHA (6)
Institutional Metric ABTS ATHA Criterion Row Edge
Market Capitalization
Scale
$1.1M $26.6M Larger Scale ATHA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-20.0% +0.0% Higher Growth ATHA
Operating Margin (TTM)
Profitability
-46.3% 0.0% Higher Margin ATHA
Net Profit Margin
Profitability
-60.8% 0.0% Higher Margin ATHA
Return on Equity (ROE)
Capital Efficiency
-60.0% -89.4% Higher ROE ABTS
52-Week Range Position
Momentum
0% ($0–$7) 80% ($0–$8) Stronger Trend ATHA
Beta / 30D Volatility
Risk Regime
1.70β · 224% Vol 6.17β · 241% Vol Lower Realized Risk ABTS
Unified Institutional Score
Composite Signal
50.5 / 100 (HOLD) 56.2 / 100 (HOLD) Higher Composite ATHA
Trailing 12M Revenue (USD)
Operating Scale
$8.3M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$73,322 EBITDA ($1.8M Net Debt (0.24x D/E)) N/A ($6.79 Book/Sh · -89.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATHA +76.66 pp
ABTS: -2.69% · ATHA: +73.97%
3M Horizon ATHA +52.44 pp
ABTS: -8.82% · ATHA: +43.62%
6M Horizon ATHA +52.44 pp
ABTS: -8.82% · ATHA: +43.62%
1Y Horizon ATHA +52.44 pp
ABTS: -8.82% · ATHA: +43.62%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABTS vs ATHA. Trailing 12-month operating profitability (ABTS -46.3% vs ATHA 0.0%) and valuation multiples (ABTS N/M vs ATHA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABTS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$8.3M
Gross Margin23.7%
Op. Margin-46.3%
ROE / Fwd P/E-60.0% · N/M
ATHA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-89.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABTS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABTS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ATHA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ATHA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABTS Moat Profile Cyclical / Execution-Driven Positioning
Capital Markets Operator
Competes within the Capital Markets value chain with $1.1M market capitalization and -46.3% operating margin.
OpEx & R&D Reinvestment 70.0% of Rev ($5.8M)
90D Engineering Disclosures 0 Published
ATHA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $26.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABTS vs ATHA Key Questions & Quantitative Answers

As of Nov 16, 2026, Athira Pharma, Inc. (ATHA) captures the overall head-to-head institutional edge over Abits Group Inc (ABTS) on higher Unified Composite conviction (56.2/100 HOLD vs. 50.5/100 HOLD) after splitting the core matrix 6–2 (led by Growth & Scale, Profitability & Quality), while ABTS wins 3–2 across the 6-pillar growth and valuation breakdown. ABTS trades at $0.31 (N/M Forward P/E, -46.3% operating margin) versus ATHA at $6.75 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ATHA earns the overall head-to-head edge with a stronger Unified Composite Score (56.2/100 HOLD vs. ABTS 50.5/100 HOLD) and 6.17β · 241% Vol risk profile, whereas ABTS leads top-line expansion (-20.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ABTS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.8); meanwhile ATHA trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 56.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ATHA leads the Growth & Scale pillar: ABTS posts -20.0% YoY revenue growth and +0.0% YoY earnings growth on $8.3M TTM revenue (23.7% gross margin, -46.3% operating margin), compared with ATHA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ABTS generates $8.3M in USD-normalized revenue versus N/A for ATHA. In operating R&D and SG&A reinvestment, ABTS deploys 70.0% of Rev ($5.8M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATHA.

ABTS screens cheaper on headline valuation multiples. ABTS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.4x EV/Revenue (0.9% EBITDA margin), whereas ATHA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABTS (-60.0% ROE) versus ATHA (-89.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ABTS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.70β · 224% Vol realized risk). By comparison, ATHA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (6.17β · 241% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.